NIH PAR · NEI · R61, R33
PAR-28-072: NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The purpose of NEI's Translational Research program (TRP) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or combination therapies for any disease or disorder of the visual system.The TRP will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase can be up to two years and will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase can be up to four years and will support…
- NOFO number
- PAR-28-072
- Type
- PAR
- Activity code
- R61R33
- Primary institute
- NEI · National Eye Institute
- Clinical trials
- Not Allowed
- Posted
- Sep 25, 2026
- Opens
- Jan 16, 2027
- Expires
- Nov 17, 2029
PAR-28-072 due dates
9 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 16, 2027 | March 16, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 16, 2027 | July 16, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 16, 2027 | November 16, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
| February 16, 2028 | March 16, 2028 | Not Applicable | July 2028 | October 2028 | December 2028 |
| June 16, 2028 | July 16, 2028 | Not Applicable | November 2028 | January 2029 | April 2029 |
| October 16, 2028 | November 16, 2028 | Not Applicable | March 2029 | May 2029 | July 2029 |
| February 16, 2029 | March 16, 2029 | Not Applicable | July 2029 | October 2029 | December 2029 |
| June 16, 2029 | July 16, 2029 | Not Applicable | November 2029 | January 2030 | April 2030 |
| October 16, 2029 | November 16, 2029 | Not Applicable | March 2030 | May 2030 | July 2030 |
What its predecessor PAR-23-200 funded
PAR-28-072 reissues PAR-23-200. Until awards appear under the new number, its funding history is the best guide to who wins under this program: 1 project and $1.4M in FY2022–FY2026.
Projects funded
1
Distinct projects, FY2022–FY2026
New awards
1
Type 1 (new project) award records
NIH funding
$1.4M
Award dollars under PAR-23-200, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 1 | 1 | $774K |
| FY2025 | 1 | 0 | $644K |
| FY2026 | 0 | 0 | $0 |
Institutions with the most funding
- Columbia University Health Sciences$1.4M · 1 project
Funding institutes
- NEI$1.4M · 2
Activity codes funded
- R612 records
Most recent new awards
- Advancing the small molecule drug candidate with dual specificity as a therapy for dry AMD (opens NIH RePORTER)
Columbia University Health Sciences · 1R61EY036287-01 · NEI · Notice Jun 7, 2024
$774KR61
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-28-072. Contact the program officer at the institute that fits your research before applying.
- NEI · National Eye Institute
- none
Related notices
NIH lists no related notices for PAR-28-072 yet.
Award terms
- Application types allowed
- New Resubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets in the R61 phase should rarely exceed 500,000 in direct costs per year. Application budgets in the R33 phase should not exceed 1,000,000 in direct costs per year.
- Project period
- The scope of the proposed project should determine the requested project award period.The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 4 years for the R33 phase. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-23-200.
Other open NOFOs for R61, R33
- RFA-NS-25-023HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)NINDS · next due Jan 15, 2027
- RFA-DC-27-004BRAIN Initiative: Exploratory Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (R61 Clinical Trial Not Allowed)NIDCD · next due Feb 11, 2027
- PAR-25-158Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)NIAAA · next due Oct 19, 2026
- PAR-25-269NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)NCCIH · next due Oct 20, 2026
- PAR-25-270NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)NCCIH · next due Oct 20, 2026
- PAR-25-225Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)NINDS · next due Oct 20, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.